TGFB1 and psoriasis: Small molecule inhibitors, neutralizing antibodies, or exogenous TGF-β application have been tested as potential tools for the management of diseases whose inflammatory component allegedly responds either to increased TGF-β signaling, like psoriasis [53,54,55] or, on the contrary, to apparently reduced TGF-β levels, which is believed to be the case for chronic wounds [37,56].